Swedish spinout Epigenovo announced plans to commercialize scFFPE‑ATAC, an assay for high‑throughput single‑cell chromatin accessibility profiling compatible with formalin‑fixed paraffin‑embedded (FFPE) samples. The company published proof‑of‑concept work in Nature Communications and is raising funds to kit the workflow and offer services. The method combines nuclei isolation from FFPE tissue, a customized FFPE‑Tn5 transposase with combinatorial indexing and a multi‑barcode split‑and‑pool scheme to generate tens of millions of cell barcodes per run. Epigenovo’s CEO argued that FFPE compatibility is essential to translate epigenetics into the clinic because most clinical samples are archived in FFPE format. If scalable, scFFPE‑ATAC could open retrospective cohorts to single‑cell epigenomic analysis and accelerate biomarker discovery in oncology and pathology; commercialization will hinge on kit robustness, throughput, and regulatory clarity for clinical use.